IGEV Followed by Autologous Transplantation for Refractory or Relapsed Hodgkin Lymphoma

• Status: Unknown status
• Trial end date: 2014-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of study is to prove IGEV regimen followed by autologous stem cell transplantation as salvage treatment in patients with refractory or relapsed Hodgkin lymphoma is effective.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Fudan University

Criteria

Inclusion Criteria:

• Age range: 18-65 years old

• Histological confirmed refractory or relapsed Hodgkin lymphoma

• With at least one site of measurable disease according to IWC criteria

• ECOG performance status 0-1

• Life expectancy of more than 3 months

• Bone marrow function: ANC≧1.5×109/L, PLT≧100×109/L, Hb≧80g/L

• Liver function: total bilirubin, ALT and AST <1.5×UNL

• Renal function: Cr<1.5×UNL, CCR≧45ml/min

• No contraindication for transplantation

Exclusion Criteria:

• No prior chemotherapy

• With more than 2 lines of prior chemotherapy exposure

• Evidence of CNS and bone marrow involvement

• History of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix

• Pregnant or lactating women

• Significant active infection